Sign inJoin waitlistJoin the waitlist

Meredith Faggen

Medical Director, Medical Oncology, Dana-Farber Brigham Cancer Center at South Shore Health · Mass General Brigham

Credentials: · · · · · ·

History

Medical Oncology · Mass General Brigham
Present
Boston Medical Center-Brighton
Present

Hematology and Medical Oncology
Brown University
2005–2008
Yale-New Haven Hospital
2002–2005
Tulane University School of Medicine
1998–2002

Research

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized…
JAMA · 2019 · 148 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Journal of Clinical Oncology · 2021 · 123 citations
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone…
Journal of Clinical Oncology · 2024 · 105 citations

Sara Tolaney
15 papers
Michael Constantine
14 papers
Natalie Sinclair
13 papers
Ann Partridge
9 papers
Eric Winer
9 papers
Nadine Tung
9 papers
Adrienne Waks
7 papers
Elizabeth Mittendorf
7 papers
Harold Burstein
7 papers
Jeanna Walsh
7 papers
SS
Sarah Sinclair
7 papers
DW
Douglas Weckstein
6 papers

Clinical trials

ALPINE: Maintenance Letrozole/Abemaciclib
Site PI · Recruiting · Phase 2
Dana-Farber Cancer Institute
2024–2029
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Site PI · Recruiting · Phase 2
Dana-Farber Cancer Institute
2021–2029